Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule

Abstract

Modification of the dosing schedule for doxorubicin (DOX) administration represents a possible method of reducing cardiotoxicity from this potent anti-cancer drug, while at the same time maintaining its cytotoxic action. The quantitative effects of modified dosage scheduling have been investigated in a clinically relevant rat model. Cardiotoxicity to DOX was assessed by the degree of reduction in cardiac output at 4–24 weeks after the intravenous administration of DOX. The effects of dose schedules involving three or six small dose administrations, over one and two weeks, were compared with that produced by large single doses of DOX. The total drug dose administered for each schedule was varied in order to establish dose–effect relationships. After a total dose of 3 mg/kg DOX, given as three or six equal small doses, there was a gradual decline in cardiac output in the first 12 weeks after drug administration. Between 12 and 24 weeks, the reduction in cardiac function was relatively stable at between 65% and 85% of that of age-matched controls for three and six equal small doses, respectively. Dose–effect curves for animals showing a ¶30% reduction in cardiac function after 12 weeks indicated the degree of reduction in cardiac function produced by the modified dose scheduling. Compared with a large single dose, larger total doses were required to produce the same severity of damage. Thus, schedules based on three and six equal small doses resulted in dose modification factor of 1.5 ‘0.23 and 2.1’ 0.28, respectively, when compared with the same effect produced by a large single dose. This appeared to be independent of the severity of cardiac damage, suggesting a simple mathematical relationship between the total acceptable dose of DOX and the dose administered at each intravenous injection. These modifications in the cardiotoxicity of DOX produced by the administration of multiple small doses were of the same order of magnitude as that produced by other methods introduced to reduce anthracycline cardiotoxicity.

Keywords

cardiotoxicity dose schedules DOX

References

Hortobagyi GN . Anthracyclines in the treatment of cancer . An overview. Drugs 1997; 54: 1–7 .

Neri B , Dini-Neri G , Bandinelli M , Bartalucci S , Ciapio A . Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspect . Int J Clin Pharmacol Ther Toxicol 1989; 27: 217–221 .

Basser RL , Green R . Strategies for the prevention of anthracycline induced cardiotoxicity . Cancer Treat Rev 1993; 19: 57–77 .

Von Hoff DD , Rozencweig M , Layard MVV , Slavik M , Muggia FM . Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases . Am J Med 1977; 62: 200–208 .

Von Hoff DD , Layard MVV , Basa P , et al. Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med 1979; 91: 710–717 .

Lipshultz SE , Colan SD , Gelber RD , Perez-Atayde S , Sallan SE , Sanders SP . Late cardiac effects of doxorubicin for lymphoblastic leukaemia in childhood . N Engl J Med 1991; 21: 324–324, 843–845 .

Carlson RW . Reducing the cardiotoxicity of the anthracyclines . Williston Park Oncol 1992; 6: 95–108 .

Casper ES , Gaynor JJ , Hajdu SI , et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors . Cancer 1991; 68: 1221–1229 .

de-Valeriola D . Dose optimization of anthracyclines . Anticancer Res 1994; 14: 2307–2313 .

10.

Hortobagyi GN , Frye D , Buzdar AU , et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma . Cancer 1989; 63: 37–45 .

11.

Shapira J , Gotfried M , Lishner M , Ravid M . Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen . Cancer 1990; 65: 870–873 .

12.

Umsawaske T , Valdivieso M , Booser DJ , et al. Weekly doxorubicin versus doxorubicin every three weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer . Cancer 1989; 64: 1995–2000 .

13.

Erttmann R , Erb N , Steinhoff A , et al. Pharmacokinetics of doxorubicin in man: dose and schedule dependence . J Cancer Res Clin Oncol 1988; 114: 509–513 .

14.

Cusack BJ , Young SP , Driskell J , Olson RD . Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit . Cancer Chemother Pharmacol 1993; 32: 53–58 .

15.

Storm G , Van Hoesel QGCM , De Groot G , Kop W , Steerenberg PA , Hillen FC . A comparative study of the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat . Cancer Chemother Pharmacol 1989; 24: 341–348 .

16.

Weiss AJ , Manthel RW . A hypothesis concerning the effect of changes in scheduling upon cardiotoxicity of adriamycin . Oncology 1983; 40: 223–226 .

17.

Torti FM , Bristow MR , Howes AE , et al. Reduced cardiotoxicity of doxorubicin delivered on a week schedule . Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745–749 .

18.

Brenner DE . Approaches to the problem of individual doxorubicin dosing schedules . Pathol Biol (Paris) 1987; 35: 31–39 .

19.

Yeung TK , Simmonds RH , Hopewell JW . Timeand dose-related modifications in cardiac function in rats after single intravenous doses of epirubicin . Radiother Oncol 1988; 11: 263–269 .

20.

Yeung TK , Simmonds RH , Hopewell JW . A functional assessment of the relative cardiotoxicity of Adriamycin and epirubicin in the rat . Radiother Oncol 1989; 15: 275–284 .

21.

Chakrabarti KB , Hopewell JW , Wilding D , Plowman PN . Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane) . Eur J Cancer 2001; 37: 1435–1442 .

22.

Hopewell JW , Duncan R , Wilding D , Chakrabarti K . Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent . Hum Exp Toxicol 2001; 20: 461–470 .

23.

Yeung TK , Simmonds RH , Hopewell JW . The relative toxicity of intravenous and intraperitoneal doses of epirubicin . Cancer Chemother Pharmacol 1989; 24: 211–218 .

24.

Yeung TK , Hopewell JW , Simmonds RH , et al. Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat . Cancer Chemother Pharmacol 1991; 29: 105–111 .

25.

Yeung TK , Jaenke RS , Wilding D , Creighton AM , Hopewell JW . The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat . Cancer Chemother Pharmacol 1992; 30: 58–64 .

26.

Anders RJ , Shanes JG , Zeller FP . Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low dose administration . Am Heart J 1986; 111: 755–759 .

27.

Weiss AJ , Metter GE , Fletcher WS . Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiotoxicity . Cancer Treat Rep 1976; 60: 813–822 .

28.

Lum BL , Svec JM , Torti FM . Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity . Drug Intell Clin Pharmacol 1985; 19: 259–264 .

29.

Valdivieso M , Burgess MA , Ewer MS , et al. Increased therapeutic index of weekly doxorubicin in the therapy of non small cell lung cancer: a prospective randomised study . J Clin Oncol 1984; 2: 207–214 .

30.

Lippens RJ , van Lier HJ , Zwagemakers JF . Tolerance of 24 hour infusions or low and high dose bolus injections of adriamycin in children . Pediatr Hematol Oncol 1987; 4: 189–197 .

31.

Chleblowski RT , Pugh RP , Bull F , et al. Concomitant razoxane and doxorubicin treatment on a weekly schedule . Cancer Treat Rep 1984; 68: 1035–1037 .

32.

Withers HR , Peters LJ . Biological basis of radiotherapy. In Fletcher GH ed. Textbook of radiotherapy. New York: Raven Press , 1980: 439–448.